Phase I Clinical Trial Data Pertaining To Bharat Biotech COVAXIN BBV152 Finally Published
The Phase I trials of COVAXIN BBV152 inactivated vaccine prepared against SARS-CoV-2 was conducted between 13th to 30th July 2020.…
PRESS RELEASE: International Virtual Conference “Supply Chain Challenges of COVID -19 Vaccines: Indian Imperative”
Introduction This report is based on International Virtual Conference “Supply Chain Challenges of COVID -19 Vaccines: Indian Imperative” that was…
Its Just for restricted use in an emergency situation! DCGI approval of Bharat Biotech & Serum Institute COVID-19 vaccines
After passing by many hurdles finally Serum Institute of India’s Covishield and Bharat Biotech’s Covaxin have received DCGI’s approval for…
Phase I Clinical Trial Data Pertaining To Bharat Biotech COVAXIN BBV152 Finally Published
The Phase I trials of COVAXIN BBV152 inactivated vaccine prepared against SARS-CoV-2 was conducted between 13th to 30th July 2020.…
PRESS RELEASE: International Virtual Conference “Supply Chain Challenges of COVID -19 Vaccines: Indian Imperative”
Introduction This report is based on International Virtual Conference “Supply Chain Challenges of COVID -19 Vaccines: Indian Imperative” that was…
Its Just for restricted use in an emergency situation! DCGI approval of Bharat Biotech & Serum Institute COVID-19 vaccines
After passing by many hurdles finally Serum Institute of India’s Covishield and Bharat Biotech’s Covaxin have received DCGI’s approval for…
Why every nation is in hurry to release COVID-19 drug/vaccine despite many concerns?
by Kamal Pratap Singh, kamal9871@gmail.com Despite various questions about effectiveness, safety and availability there seems a hurry to release COVID…
Plasmodium vivax conundrum: An obstacle to malaria elimination in India
by Shrikant Nema1, 2 1Division of Vector-Borne Diseases, ICMR-National Institute of Research in Tribal Health, Jabalpur 482 003, Madhya Pradesh,…
AstraZeneca Dives into Rare Diseases With $39 Billion Acquisition of Alexion
AstraZeneca announced it is acquiring Alexion Pharmaceuticals for $39 billion. Alexion shareholders will get $60 in cash and 2.1243 AstraZeneca…
Tesla to Build Mobile RNA Microfactories for CureVac’s COVID-19 Vaccine
Tesla, the electric car company founded and run by Elon Musk, is building mobile molecular printers to assist Germany’s CureVac in manufacturing…
NIV Pune Scientists first to deposit gene sequence of coronavirus from the country
Four Indian scientists from ICMR-NIV deposited first genome of coronavirus from India to NCBI Genbank. The online accession link of…
DBT/Wellcome Trust India Alliance and RTI International India set up a ‘COVID-19 Catalytic Partnership’ for India
DBT/Wellcome Trust India Alliance (India Alliance or IA) and RTI International India join forces to set up a COVID-19 Catalytic…
Its Just for restricted use in an emergency situation! DCGI approval of Bharat Biotech & Serum Institute COVID-19 vaccines
After passing by many hurdles finally Serum Institute of India’s Covishield and Bharat Biotech’s Covaxin have received DCGI’s approval for…
Are Bill Gates’s Billions Distorting Public Health Data?
In the early days of the pandemic, the IHME projected a far less severe outbreak than other models, which drew…
AstraZeneca Dives into Rare Diseases With $39 Billion Acquisition of Alexion
AstraZeneca announced it is acquiring Alexion Pharmaceuticals for $39 billion. Alexion shareholders will get $60 in cash and 2.1243 AstraZeneca…
